ArticlePDF Available

Clinical, Biological, Immunological and Therapeutic Profile of Patients Co-Infected with HIV-HBV and/or HCV in Kinshasa, in the Democratic Republic of the Congo: Multicenter Cross-Sectional Study

Authors:
Open Journal of Gastroenterology, 2022, 12, *-*
https://www.scirp.org/journal/ojgas
ISSN Online: 2163-9469
ISSN Print: 2163-9450
DOI:
10.4236/***.2022.***** **** **, 2022 1 Open Journal of Gastroenterology
Clinical, Biological, Immunological and
Therapeutic Profile of Patients Co-Infected with
HIV-HBV and/or HCV in Kinshasa, in the
Democratic Republic of the Congo: Multicenter
Cross-Sectional Study
Jean-Paul Kimpiatu Mayimona1, Aliocha Nkodila Natuhoyila2*, Antoine Tshimpi Wola Yaba1,
Charles Mbendi Nlombi1, François Lepira Bompeka3, Thérèse Ndarabu1, Jean Jacques Matimbo1,
Youyou Paka1, Sebastien Mbendi Nsukini1, Fiston Mbutiwi4, Jean Robert Makulo Rissassi3,
Hippolyte Situakibanza Nani-Tuma5, Benjamin Longo Mbenza6
1Garstroenterology Department, University of Kinshasa, Kinshasa, Democratic Republic of the Congo
2Faculty of Family Medicine and Primary Health Care, Protestant University in Congo, city, Democratic Republic of the Congo
3Department of Nephrology, University of Kinshasa, Kinshasa, Democratic Republic of the Congo
4Department of Nephrology, University of Kikwit, Kikwit, Democratic Republic of the Congo
5Department of Infectious Diseases, University of Kinshasa, Kinshasa, Democratic Republic of the Congo
6Department of Cardiology, University of Kinshasa, Kinshasa, Democratic Republic of the Congo
Email: *nkodilaaliocha@gmail.com
Abstract
Background and Objective:
HIV infection is often associated with HBV and
HCV infection, together leading to high morbidity and mortality in develop-
ing countries. The objective of this study is to describe the clinical, biological,
immunological and therapeutic profile of patients co-infected with HIV-
HBV
and/or HCV.
Methods:
A cross-sectional and descriptive st
udy including 180
people living with HIV (PLWHIV) in the city of Kinshasa province was con-
ducted. Sociodemographic, clinical, biological and serological characteristics
were analyzed.
Results:
The frequency of HIV-HBV/HCV co-
infection was
23.9%. The distribution of age and sex of patients did not differ significantly
according to co-
infection status. The notion of pedicure and manicure was
significantly more observed in patients free from viral hepatitis (51.1%
versus
32.6%, p = 0.034). The median duration
of knowledge of the HIV status
which was longer in the co-infected (4 years
versus
2 years, p = 0.022). A
lower median level of GPT was observed in co-
infected compared to other
patients (14 IU/L
vers
us 20 IU/L, P = 0.041). Serum albumin (3.1 g/L versus
How to cite this paper:
Author 1, Author
2 and Author 3 (20
22) Paper Title.
Open
Journal of Gastroenterology
,
12
, *-*.
https://doi.org/10.4236/***.202
2.*****
Received:
**** **, ***
Accepted:
**** **, ***
Published:
**** **, ***
Copyright ©
2022 by author(s) and
Scientific
Research Publishing Inc.
This work is licensed under the Creative
Commons Attribution International
License (CC BY
4.0).
http://creativecommons.org/licenses/by/4.0
/
Open Access
J.-P. K. Mayimona et al.
DOI:
10.4236/***.2022.***** 2 Open Journal of Gastroenterology
3.3 g/L, p = 0.034) and prothrombin (58.3%
versus
65.6%, P = 0.045) were
lower in HIV co-infected -VHB and/or VHC. The median INR was higher in
co-infected than in other patients (1.6
versus
1.4; P
= 0.009). Patients without
therapy Antiretroviral (TARV) medication were more numerous in co-infected
(20.9% versus 8.0%, p = 0.025).
Conclusions:
The profile of PLWHIV was
dominated by the presence of pedicures and manicures with high transami-
nases and without anti-viral treatment.
Keywords
HIV-HCV-HBV Co-Infection, Clinical Profile, Biology, TARVs, Kinshasa
1. Introduction
The hepatotropic and lymphotropic virus, HCV and HBV induce a specific cy-
totoxic T immune response which, combined with the production of interferon
γ
, allows in some patients to eliminate the virus with a frequency of around 11%
to 32% in HIV-HCV/HBV co-infected patients [1]. However, the chances of
spontaneous recovery from acute hepatitis C or B in people living with HIV
(PLWHIV) are lower than without HIV infection, ranging from 11% to 32%
[2]-[8]. The transition to the chronic phase of viral C and B infection is the re-
sult of the modulating effect exerted by the virus itself on the balance established
after infection between costimulatory and pro/anti-apoptotic molecules, between
Treg cells and T-helpers but also the establishment of escape mechanisms that
allow the virus to remain in the body indefinitely, mainly in hepatocytes [9].
However, there is evidence of HCV or HBV replication in other cell types in-
cluding lymphocytes. Chronic viral replication of HCV and HBV occurs against
a background of permanent immune activation, higher in HIV-HCV/HBV
co-infected patients [10], whose long-term effects are only just beginning to be
identified and quantified. Several studies have thus demonstrated a higher vascular
risk in HCV/HBV mono-infected patients (stroke, obliterating arterial disease of
the lower limbs, coronary artery disease), as well as renal failure (by nephroangios-
clerosis and extra-membranous glomerulonephritis), diabetes mellitus and can-
cers, especially extrahepatic, the first of them identified being non-Hodgkin’s ma-
lignant lymphoma [11] [12] [13] [14]. In the Democratic Republic of the Congo,
we do not have sufficient data to support the role of HCV/HBV co-infection in
patients infected with HIV. The objective of this study is to describe the clinical,
biological, immunological and therapeutic profile of patients co-infected with
HIV-HBV and/or HCV.
2. Methods
It was a cross-sectional and descriptive study. It took place in the city of Kinsha-
sa, the political capital of the Democratic Republic of the Congo. In this city,
J.-P. K. Mayimona et al.
DOI:
10.4236/***.2022.***** 3 Open Journal of Gastroenterology
HIV care is organized in all general hospitals, in certain general and university
hospitals, in certain private medical centers and in the medical training of cer-
tain NGOs. Depending on the availability and completeness of the information
sought in our study, we considered two NGOs located in urban-rural areas,
namely: the Pediatric Foundation of Kimbondo and the NGO Community Ac-
tions AIDS/Better Future for Orphans of Congo (ACS/AMO-Congo) which are
among the oldest centers in Kinshasa for HIV care. It was during the period
from November 10, 2013 to January 10, 2014. The study had consecutively in-
cluded elderly people of at least 18 years known to have HIV who consulted
during the study period at the two selected sites and who freely consented to
participate in the study. Inclusion criteria were to be PLWHIV at least 18 years
of age consenting to participate in the study and followed in one of the two
treatment centers selected for the study, to have a medical file including the pa-
rameters sought. To carry out the present study, were used as materials data col-
lection sheet, informed consent sheet, strips for rapid qualitative tests HBsAg
and AcVHC of the brand ACCURATE of Indian manufacture, quantitative
tests for the determination of the markers of the hepatitis B (ELISA) brand
DIALAB Austrian manufacture, test for determination of HCV antibodies
(ELISA) brand DIALAB Austrian manufacture, tests for evaluation of hepatic
synthetic function.
The actual data collection involved 3 stages: 1) administering a questionnaire
to patients to collect socio-demographic information, medical history and risk
behaviors for viral hepatitis; 2) the blood test for the determination of markers of
the hepatic functions studied and of HBV and HCV; 3) analysis of the medical
file of each patient selected in search of clinical, immunological and therapeutic
information relating to HIV infection. Socio-demographic parameters included
age, sex, occupation, marital status, level of education and religion. Regarding
the medical history and risky behavior, we looked for the concept of previous
blood transfusion, vaccination against HBV, the number of sexual partners, the
type of sexual intercourse, the concept of scarification, circumcision, excision,
piercing, drug addiction, knowledge of ones HBV and HCV serological status
and the notion of surgical intervention in the past. The analysis of the medical
file of each patient allowed us to gather information on the year of the diagnosis
of HIV, the clinical stage of the HIV infection, the current ARV treatment regi-
men and, if applicable, the highest rate. recent CD4; only CD4 counts not older
than 3 months before the survey were taken into account. On the blood test, the
HBV biological markers sought were HBs Ag, anti-HBs Ab, anti-HBc Ab, HBe
Ag and anti-HBe Ab. For HCV, total anti-HCV Abs were assayed. Transami-
nases (SGOT and SGPT) were the desired markers of hepatic cytolysis. To ex-
plore cholestasis, we assayed for
γ
GT, total and direct bilirubin as well as alka-
line phosphatases. To assess hepatic synthetic function, prothrombin, serum al-
bumin, and INR were assayed. In terms of the collection process, any patient se-
lected for the study received, after consultation by the centers medical team, the
J.-P. K. Mayimona et al.
DOI:
10.4236/***.2022.***** 4 Open Journal of Gastroenterology
survey questionnaire. After completing the questionnaire, the patient was di-
rected to the laboratory with a token bearing an identification code. Once ar-
rived at the laboratory, a 5 cc venous blood sample was taken in two tubes, a dry
tube for hematological and biochemical analyzes and another tube with citrate
for serological analyzes. The samples were centrifuged using a German brand
A-RD-42-26 device at 1500 revolutions/min/5min, decanted and then stored in
the refrigerator at a temperature between 2˚C to 8˚C at the site laboratories. stu-
dies. Qualitative tests for HBsAg and for total HCV antibodies were performed
on site; the rest of the samples were sent to the Lomo Médical laboratory where
hematological, biochemical and serological analyzes were carried out.
A spectrophotometer of the brand Spectrumand a Bain Marie of the
HUMAN brand and ELISA reader HIMARETADR-FINGLE of the HUMAN
brand were used to carry out the hematological and biochemical analyzes ac-
cording to the manufacturers standards. Kinetic methods for GOT, GPT, PAL,
γGT; enzymatic for serum albumin, total and direct bilirubin, prothrombin and
INR; and immunoenzymatic type ELISA for quantitative tests for viral hepatitis
B and C were used. The results were transcribed on an ad hoc form with the
corresponding codes.
Definition of concepts
Anti-HBs Ab were found to be positive when in the Elisa test, the anti-HBs Ab
titre was >12 IU/L [15];
HIV-HBV co-infection was selected on the basis of the positivity of HBsAg in
HIV + patients [15];
HIV-HCV coinfection was selected on the basis of the positivity of anti-HCV
Ab in HIV + patients [15].
Statistical analyzes
The processing and analysis of the data collected was carried out using SPSS
version 21 software. During the analysis, the age of the patients was categorized
into tertiles (<40 years, 40 - 49 years and ≥50 years). CD4 counts were dichoto-
mized at the threshold of their median value (3 years and 303 cells/mm3, respec-
tively). The descriptive statistics applied include the mean ± standard deviation
for continuous quantitative variables with symmetric distribution, the median
with extreme values for those with asymmetric distribution, and relative (%)
and/or absolute (n) frequencies for qualitative variables. For comparison of
means and medians, Students t test and Wilcoxon/Mann-Whitney nonparame-
tric test were applied. For the analysis of the contingency tables, we used Pear-
sons chi-square test or Fishers exact test or linear trend chi-square, as appro-
priate. For the tests used, the statistical significance level retained was P value <
0.05.
Ethical considerations
The protocol was submitted to the ethics committee of the School of Public
Health of the University of Kinshasa and was agreed at number ESP/CE/012/14.
Thus, when recruiting patients, anonymity and confidentiality were guaranteed.
J.-P. K. Mayimona et al.
DOI:
10.4236/***.2022.***** 5 Open Journal of Gastroenterology
3. Results
Clinical profile of HIV-HBV and/or HCV co-infected of the 180 PLWHIV in-
cluded in the study, 43 had an HIV-HBV-HCV coinfection, a frequency of
23.9% coinfection.
Table 1 presents the clinical profile of all patients and the HIV-HBV and/or
HCV co-infection status.
The age and sex distribution of the patients did not differ significantly according
to co-infection status. The notion of pedicure and manicure was significantly more
Table 1. Clinical characteristics of patients according to HIV-HBV and/or HCV co-infection
status.
Variable
Over all
(n = 180)
HIV
(n = 137)
HIV+/HBV+/
HCV (n = 43)
Age (year)
44.2 ± 11.0
44.6 ± 10.6
42.8 ± 12.2
<40%
33.3
29.9
44.2
40% - 49%
34.4
38.0
23.3
≥50%
32.2
32.1
32.6
Gender, %
Female
76.7
78.1
72.1
Male
23.3
21.9
27.9
Transfusion, %
32.8
33.6
30.2
Pedicure and manicure, %
46.7
51.1
32.6
Jaundice in the past, %
5.6
5.1
7.0
Concept of anti-HBV vaccination, %
1.1
1.5
0.0
Scarification, piercing, excision, %
40.0
39.4
41.9
Substance addiction, %
6.7
5.1
11.6
Number of sexual partners, %
1
61.1
64.2
51.2
>1
38.9
35.8
48.8
Condom use, %
20.0
21.2
16.3
Surgery in the past, %
45.0
43.8
48.8
Knowledge of status
1.1
0.7
2.3
Duration of HIV infection (years)
3 (1 - 20)
4 (1 - 15)
2 (1 - 20)
Clinical stage of HIV, %
I
10.0
8.0
16.3
II
30.6
28.5
37.2
III
46.1
49.6
34.9
IV
13.3
13.9
11.6
J.-P. K. Mayimona et al.
DOI:
10.4236/***.2022.***** 6 Open Journal of Gastroenterology
observed in patients free from viral hepatitis (51.1% versus 32.6% in co-infected,
P = 0.034). The same is true of the median duration of knowledge of the HIV
status, which was significantly longer in this latter group (4 years versus 2 years
in the co-infected, P = 0.022). The other characteristics noted, in this case, a his-
tory of transfusion (32.8%), jaundice (5.6%), anti-HBV vaccination (1.1%), sca-
rification, piercing and excision (40%), drug addiction (6.7%) or surgery (45%),
condom use (20%), number of sexual partners, or clinical stage of HIV infection
did not differ significantly according to co-infection status.
Biological profile of HIV-HBV and/or HCV co-infected
The data are indicated in Table 2.
Biologically (Table 1), the median levels of SGOT (23 IU/L), gamma-GT (28
IU/L), alkaline phosphatase (160 IU/L), total bilirubin (0.4 g/L) and direct bili-
rubin (0.1 g/L) did not differ significantly depending on coinfection status. In
contrast, a significantly lower median level of SGPT was observed in HIV-HBV
and/or HCV coinfected compared to other patients (14 IU/L
versus
20 IU/L; P =
0.041). The same is true of the mean serum albumin levels (3.1 g/L
versus
3.3
g/L; P = 0.034) and prothrombin (58.3%
versus
65.6%; P = 0.045) which were
significantly lower in the group of HIV-HBV and/or HCV co-infected. The me-
dian INR was significantly higher in co-infected than in other patients (1.6
ver-
sus
1.4; P = 0.009).
Therapeutic profile of HIV-HBV and/or HCV co-infected
The results are presented in Table 3.
The ARV therapeutic profile of the patients differed significantly depending
on the co-infection status. In particular, more patients without ARV medication
were observed in the group of HIV-HBV and/or HCV co-infected (20.9% versus
8.0%; p = 0.025) (Table 3).
Immunological profile of HIV-HBV and/or HCV co-infected
Table 2. Laboratory characteristics of patients according to HIV-HBV and/or HCV
co-infection status.
Variable
Over all
(n = 180)
HIV
(n = 137)
HIV+/HBV+/
HCV (n = 43)
P
SGOT (UI/L)
23 (1 - 748)
25 (1 - 138)
18 (2 - 748)
0.055
SGPT (UI/L)
19 (4 - 150)
20 (4 - 150)
14 (4 - 144)
0.041
Gamma-GT (UI/L)
28 (4 - 232)
30 (4 - 232)
24 (4 - 129)
0.623
Alkaline phosphatases (IU/L)
160 (18 - 689)
157 (34 - 689)
182 (18 - 565)
0.116
Total bilirubin (g/L)
0.4 (0.1 - 3.9)
0.4 (0.1 - 1.2)
0.5 (0.1 - 3.9)
0.313
Direct Bilirubin (g/L)
0.1 (0.0 - 1.0)
0.1 (0.0 - 0.8)
0.1 (0.0 - 1.0)
0.822
Serum albumin (g/L)
3.2 ± 0.6
3.3 ± 0.6
3.1 ± 0.6
0.034
Prothrombin (%)
63.8 ± 21.0
65.6 ± 21.0
58.3 ± 20.3
0.045
INR
1.4 (1.0 - 5.9)
1.4 (1.0 - 5.9)
1.6 (1.0 - 5.9)
0.009
Data are expressed as mean ± standard deviation or median (range).
J.-P. K. Mayimona et al.
DOI:
10.4236/***.2022.***** 7 Open Journal of Gastroenterology
Table 3. Therapeutic characteristics of patients according to HIV-HBV and/or HCV
co-infection status.
Variable
Over all
(n = 180)
HIV
(n = 137)
HIV+/HBV+/HCV
(n = 43)
P
ARV treatment, %
0.025
No treatment
11.1
8.0
20.9
AZT + 3TC + NVP
73.9
73.7
74.4
TDF + 3TC + EFV
11.1
13.9
2.3
ABC + DDI + [ALUVIA ou LPV/r]
3.9
4.4
2.3
The median CD4 lymphocyte count did not differ significantly depending on
the HIV-HBV/C co-infection status (347 cells/mm3 in the co-infected patients
versus 303 cells/mm3 in the non-co-infected; p = 0.606).
4. Discussion
The purpose of this study was to describe the clinical, biological and therapeutic pro-
file of HIV-HBV-HCV co-infection in Kinshasa. With regard to HIV-HBV/HCV
co-infection, the age groups < 40 years, 40 - 49 years and ≥50 years represented a
frequency of 44.2%, 23.3%, 32.6%, respectively. %. The difference in frequency
between age groups was not statistically significant (P =). These results are con-
tradictory to other epidemiological studies reported in the literature [16] [17]
[18]. The discrepancy of our results compared to the aforementioned studies is
justified by the fact that the data of the literature read so far and which mention
the age do not speak about the importance of the infection with HBV and HCV
compared to each age category. The difference in work methodology took us
away, but also the population sizes of the aforementioned studies were almost 2
to 20 times larger than ours [xxx].
In addition, the female sex is more predominant (72.1%) than the male sex
(27.9%). This result is consistent with the fact that in the general population fe-
male PLHIV are more common. The practice of manicures and pedicures has
emerged as the main risk factor for the occurrence of HIV-hepatitis B and/or C
co-infection alongside the duration of the HIV infection. The laboratory profile
of co-infected patients was dominated by the high level of GPT 14 (4 - 144), an
increase to 3x> normal. These results are close to those of Idoko in Nigerian
[19]. A low level of serum albumin, prothrombin and INR was observed with
respectively 3.1 ± 0.6 (P = 0.034), 58.3 ± 20.3 (P = 0.045), 1.6 (1.0 - 5.9) (P =
0.009).
Regarding the treatment of hepatitis C and B in PLWHIV, this study confirms
the strong dynamics of treatment since the availability of direct viral agents with
an efficacy and a tolerance comparable to those observed in people with
mono-infected with HIV, including in patients with HIV-HCV/HBV [20]. This
dynamic is also observed routinely in France [21]. However, there is a significant
percentage of PLWHIV co-infected with HCV and HBV still to be treated, as
J.-P. K. Mayimona et al.
DOI:
10.4236/***.2022.***** 8 Open Journal of Gastroenterology
shown by a survey conducted in June 2016 (
i.e.
almost 2 years after the possibil-
ity of treating all co-infected PLWHIV), at within the ICONE cohort comprising
10,087 PLHIV followed in the centers of the Bourgogne-Franche Comté, Grand
Est and Hauts de France regions [21].
The limitations of our study are the fact that it was not multicenter therefore
not representative in our country, the cost of biological tests did not allow the
study to be extended to other sites. The methodology used in our study does not
identify the factors associated with HIV-HBV-HCV infection. We did not test
whether the infection was new or old in relation to anti HBc Ab, or assay the
viral DNA to separate cases of cure from that of infection.
Apart from these limitations, this work constitutes the first research carried
out in this field in Kinshasa. The participation rate which is particularly inter-
esting since the study was carried out in a developing country where the inhabi-
tants are not used to participating in epidemiological studies and research. The
biological analyzes were carried out in one of the reference laboratories in our
country.
5. Conclusions
The results of our study on the frequency and the clinical-biological profile of
HIV and hepatitis B and C virus co-infection in an HIV + population in Kin-
shasa have shown that:
Hepatitis B and C are frequent in this population;
The notion of pedicure and manicure as well as the duration of HIV infection
emerged as the clinical profile most associated with HIV/hepatitis B and/or C
virus co-infection;
Acute and occult hepatitis B was the most common typological profile;
A low SGPT transaminase level, a low serum albumin and prothrombin level
as well as a high INR level were the laboratory profile most associated with
HIV/viral hepatitis B co-infection and/or C.
Authors Contributions
All authors contributed to data analysis, drafting or revising the article, have
agreed on the journal to which the article will be submitted, gave final approval
of the version to be published, and agree to be accountable for all aspects of the
work.
Conflicts of Interest
The authors declare no conflicts of interest regarding the publication of this pa-
per.
References
[1] Ferri, C., Sebastiani, M., Giuggioli, D., Colaci, M., Fallahi, P., Piluso, A.,
et al
. (2015)
Hepatitis C Virus Syndrome: A Constellation of Organ- and Non-Organ Specific
J.-P. K. Mayimona et al.
DOI:
10.4236/***.2022.***** 9 Open Journal of Gastroenterology
Autoimmune Disorders, B-Cell Non-Hodgkin’s Lymphoma, and Cancer.
World
Journal of Hepatology
, 7, 327-343. https://doi.org/10.4254/wjh.v7.i3.327
[2] Seaberg, E.C., Witt, M.D., Jacobson, L.P., Detels, R., Rinaldo, C.R., Margolick, J.B.,
et al
. (2015) Spontaneous Clearance of the Hepatitis C Virus among Men Who
Have Sex with Men.
Clinical Infectious Diseases
, 61, 1381-1388.
[3] Piroth, L., Larsen, C., Binquet, C., Alric, L., Auperin, I., Chaix, M.L.,
et al
. (2010)
Treatment of Acute Hepatitis C in Human Immunodeficiency Virus-Infected Pa-
tients: The HEPAIG Study.
Hepatology
, 52, 1915-1921.
https://doi.org/10.1002/hep.23959
[4] Thomson, E.C., Fleming, V.M., Main, J., Klenerman, P., Weber, J., Eliahoo, J.,
et al
.
(2011) Predicting Spontaneous Clearance of Acute Hepatitis C Virus in a Large
Cohort of HIV-1-Infected Men.
Gut
, 60, 837-845.
https://doi.org/10.1136/gut.2010.217166
[5] Ingiliz, P., Steininger, K., Schuetze, M., Dupke, S., Carganico, A., Krznaric, I.,
et al
.
(2014) Acute Hepatitis C Virus (HCV) Infection in the Setting of HIV Coinfection:
A Single-Centre 10-Year Follow-Up.
Journal of the International AIDS Society
, 17,
Article ID: 19638. https://doi.org/10.7448/IAS.17.4.19638
[6] Ward, C. and Lee, V. (2014) Experience of Acute Hepatitis C and HIV Co-Infection
in an Inner City Clinic in the UK.
Journal of the International AIDS Society
, 17, Ar-
ticle ID: 19639. https://doi.org/10.7448/IAS.17.4.19639
[7] Hullegie, S.J., Van Den Berk, G.E., Leyten, E.M., Arends, J.E., Lauw, F.N., Van Der
Meer, J.T.,
et al
. (2016) Acute Hepatitis C in the Netherlands: Characteristics of the
Epidemic in 2014.
Clinical Microbiology and Infection
, 22, 209.E1-209.E3.
https://doi.org/10.1016/j.cmi.2015.10.012
[8] Wandeler, G., Schlauri, M., Jaquier, M.E., Rohrbach, J., Metzner, K.J., Fehr, J.,
et al
.
(2015) Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study:
Changes in Treatment Uptake and Outcomes between 1991 and 2013.
Open Forum
Infect Dis
, 2, ofv026. https://doi.org/10.1093/ofid/ofv026
Groupe d’experts pour la prise en charge du VIH (2017) Prise en charge médicale
des personnes vivant avec le VIH. Co-infections par les virus des hépatites (mai
2017), CNS, ANRS, city, 84.
[9] Larrubia, J.R., Moreno-Cubero, E., Lokhande, M.U., Garcia-Garzon, S., Lazaro, A.,
Miquel, J.,
et al
. (2014) Adaptive Immune Response During Hepatitis C Virus
Infection.
World Journal of Gastroenterology
, 20, 3418-3430.
https://doi.org/10.3748/wjg.v20.i13.3418
[10] Gonzalez, V.D., Falconer, K., Blom, K.G., Reichard, O., Morn, B., Laursen, A.L.,
et
al
. (2009) High Levels of Chronic Immune Activation in the T-Cell Compartments
of Patients Coinfected with Hepatitis C Virus and Human Immunodeficiency Virus
Type 1 and on Highly Active Antiretroviral Therapy Are Reverted by Alpha Inter-
feron and Ribavirin Treatment.
Journal of Virology
, 83, 11407-11411.
https://doi.org/10.1128/JVI.01211-09
[11] Lee, M.H., Yang, H.I., Lu, S.N., Jen, C.L., You, S.L., Wang, L.Y.,
et al
. (2012) Chron-
ic Hepatitis C Virus Infection Increases Mortality from Hepatic and Extrahepatic
Diseases: A Community-Based Long-Term Prospective Study.
The Journal of Infec-
tious Diseases
, 206, 469-477.
[12] Domont, F. and Cacoub, P. (2016) Chronic Hepatitis C Virus Infection, a New Car-
diovascular Risk Factor?
Liver International
, 36, 621-627.
https://doi.org/10.1111/liv.13064
[13] Allison, R.D., Tong, X., Moorman, A.C., Ly, K.N., Rupp, L., Xu, F.,
et al
. (2015) In-
J.-P. K. Mayimona et al.
DOI:
10.4236/***.2022.***** 10 Open Journal of Gastroenterology
creased Incidence of Cancer and Cancer-Related Mortality among Persons with
Chronic Hepatitis C Infection, 2006-2010.
Journal of Hepatology
, 63, 822-888.
https://doi.org/10.1016/j.jhep.2015.04.021
[14] Iqbal, T., Mahale, P., Turturro, F., Kyvernitakis, A. and Torres, H.A. (2016) Preva-
lence and Association of Hepatitis C Virus Infection with Different Types of Lym-
phoma.
International Journal of Cancer
, 138, 1035-1037.
https://doi.org/10.1002/ijc.29845
[15] Yombi, J.C., Marot, J.C., DE Visscher, N., Ausselet, N., Vincent, A. and Vandercam,
B. (2007) Co-infection par le virus de l’immunodéficience humaine et le virus de
l’hépatite B et le virus de l’hépatite C. Louvain Médical.
Louvain Médical
, 126,
238-248.
[16] Ntagirabiri, R., Ngendakumana, F. and Niyangabo, T. (year) Co-infection par le
virus de l’immunodéficience humaine et le virus de l’hépatite C au Burundi.
J Afr
Hepatol Gastroenterologie
, vol, p.
[17] Lodenyo, H., Schoub, B., Ally, R., Kairu, S. and Segal, I. (2000) Hepatitis B and C
Virus Infections and Liver Function in AIDS Patients at Chris HANI Baragwanath
Hospital Johannesburg.
East African Medical
, 77, 13-15.
https://doi.org/10.4314/eamj.v77i1.46369
[18] Benhamou, Y., Katlama, C. and Lunel, F. (1996) Effects of Lamivudine on Replica-
tion of Hepatitis B Virus in HIV-Infected Men.
Annals of Internal Medicin
, 125,
705-712. https://doi.org/10.7326/0003-4819-125-9-199611010-00001
[19] Idoko, X., Meloni, S., Muazu, M., Nimzing, L., Badung, B., Hawkins, C.,
et al
. (2009)
Impact of Hepatitis B Virus Infection on Human Immunodeficiency Virus Re-
sponse to Antiretroviral Therapy in Nigeria.
Clinical Infectious Diseases
, 49,
1268-1273. https://doi.org/10.1086/605675
[20] Shire, N.J., Rouster, S.D., Rajicic, N. and Sherman, K.E. (2004) Occult Hepatitis B in
HIV-Infected Patients.
Journal of Acquired Immune Deficiency Syndromes
, 36,
869-875. https://doi.org/10.1097/00126334-200407010-00015
[21] Minuk, G., Sin, D.F., Greenberg, R., Zhang, M., Hawkins, K., Uhanova, J.,
et al
.
(2004) Occult Hepatitis B Infection in North American Adult Hemodialysis Patient
Population.
Hepatology
, 40, 1072-1077. https://doi.org/10.1002/hep.20435
J.-P. K. Mayimona et al.
DOI:
10.4236/***.2022.***** 11 Open Journal of Gastroenterology
APPENDIX 2: Data Collection Sheet on the Prevalence of
Co-Infections by Hepatitis B and C Viruses and
Evaluation of Hepatic Function in an HIV+
Population in Kinshasa
1. Identity
Name…………………………………………………………………………………
Post name:…………………………………….............................……………………
Age:………………...........................................................................................................
Sex:……………………………………………………………………………………
Race:….………………………………………………………………………………
Civil status:……………………......................................................................................
Profession:………………………………………………………………………….
Address:………………………………………………………………………………
Province of origin:…………………………………………………………………
Level of studies completed:…………………………………………………………
Religion:……………………………………………………………………………
2. Background
Blood transfusion…………………... Yes No
Blood group…………….................... Yes No
Pedicure and Manicure …………… Yes No
Jaundice …………………………… Yes No
Previous vaccination against
Hepatitis B………………………… Yes No
Scarifications……………………… Yes No
Circumcision……………………… Yes No
Piercing…………………………… Yes No
Circumcision……………………… Yes No
Drug addiction…………………… Yes No
Number of sexual partners One Several Yes No
Safe sex Yes No
HBV or HCV known before HIV diagnosis Yes No
Year of HIV diagnosis……………………………..……..……..……..……..……..
Current antiretroviral treatment……………………………………………………
Antiretroviral regimens……………………………………………………………
Surgical intervention in the past Yes No
Current stage of HIV infection……………………………………………………
3. Paraclinical
at. Medical Biology
Qualitative HBs antigen…………………… Positive Negative
Qualitative HCV antibody………………… Positive Negative
J.-P. K. Mayimona et al.
DOI:
10.4236/***.2022.***** 12 Open Journal of Gastroenterology
HBs antigen (ELISA):………...……...……. Positive Negative
HBs Antibody (ELISA)……………...…...… Positive Negative
HBc Antibody (ELISA)…………...……...… Positive Negative
HBe antigen (ELISA)……………...……...… Positive Negative
HBe (ELISA) Antibody ……...………...…... Positive Negative
Total VH Antibodies (ELISA) …...………... Positive Negative
ALAT:……………. Normal High Specify the value:…...................................
AST:…………… Normal High Specify value:………...........................…
Gamma GT …….. Normal High Specify value……………………………
Serum albumin… Normal Low Specify value………………………..……
Prothrombin …… Normal Low Specify value…………………………..…
Alkaline phosphatase Normal Low Specify value………………………….…
Total bilirubin Normal High Specify value……………………………
Direct bilirubin Normal High Specify the value………………………
CD4 (specify value):…………………………………………………………………
Done in Kinshasa, on………../……../201…….….
... The clinic of HIV infection has been the subject of several publications in our community [6] [7] [8]. Nevertheless, there are few data on PLHIV starting ARV Treatment (ART) nor on their clinical profile in our environment for the last few years, especially since the introduction of Dolutegravir in 2019. ...
... Since the transition to Dolutegravir (DTG) in 2019, several studies have been documented on PLHIV in the DRC and particularly in Kinshasa [3]- [8]. Nevertheless, no study was found on the sociodemographic and anthropometric pro- ...
Article
Full-text available
Within the Dutch Acute HCV in HIV Study, a surveillance system was initiated to estimate the incidence of hepatitis C virus (HCV) infections in 2014. Following the Dutch HIV treatment guidelines, HIV-positive men having sex with men (MSM) in 19 participating centers were screened. Ninety-nine acute HCV infections were reported, which resulted in a mean incidence of 11 per 1000 patient-years of follow-up. Unfortunately, the HCV epidemic among Dutch HIV-positive MSM is not coming to a halt. © 2015 European Society of Clinical Microbiology and Infectious Diseases.
Article
Full-text available
Background. The hepatitis C virus (HCV) epidemic is evolving rapidly in patients infected with human immunodeficiency virus (HIV). We aimed to describe changes in treatment uptake and outcomes of incident HCV infections before and after 2006, the time-point at which major changes in HCV epidemic became apparent. Methods. We included all adults with an incident HCV infection before June 2012 in the Swiss HIV Cohort Study, a prospective nationwide representative cohort of individuals infected with HIV. We assessed the following outcomes by time period: the proportion of patients starting an HCV therapy, the proportion of treated patients achieving a sustained virological response (SVR), and the proportion of patients with persistent HCV infection during follow-up. Results. Of 193 patients with an HCV seroconversion, 106 were diagnosed before and 87 after January 2006. The proportion of men who have sex with men increased from 24% before to 85% after 2006 (P < .001). Hepatitis C virus treatment uptake increased from 33% before 2006 to 77% after 2006 (P < .001). Treatment was started during early infection in 22% of patients before and 91% after 2006 (P < .001). An SVR was achieved in 78% and 29% (P = .01) of patients treated during early and chronic HCV infection. The probability of having a detectable viral load 5 years after diagnosis was 0.67 (95% confidence interval [CI], 0.58–0.77) in the group diagnosed before 2006 and 0.24 (95% CI, 0.16–0.35) in the other group (P < .001). Conclusions. In recent years, increased uptake and earlier initiation of HCV therapy among patients with incident infections significantly reduced the proportion of patients with replicating HCV.
Article
Full-text available
Persons chronically infected with the hepatitis C virus (HCV) may be at higher risk for developing and dying from non-liver cancers than the general population. 12,126 chronic HCV-infected persons in the Chronic Hepatitis Cohort Study (CHeCS) contributed 39,984 person-years of follow-up from 2006 to 2010 and were compared to 133,795,010 records from 13 Surveillance, Epidemiology and End Results Program (SEER) cancer registries, and approximately 12 million U.S. death certificates from Multiple Cause of Death (MCOD) data. Measurements included standardized rate ratios (SRR) and relative risk (RR). The incidence of the following cancers was significantly higher among patients with chronic HCV infection: liver (SRR, 48.6 [95% CI, 44.4-52.7]), pancreas (2.5 [1.7-3.2]), rectum (2.1 [1.3-2.8]), kidney (1.7 [1.1-2.2]), non-Hodgkin lymphoma (NHL) (1.6 [1.2-2.1]), and lung (1.6 [1.3-1.9]). Age-adjusted mortality was significantly higher among patients with: liver (RR, 29.6 [95% CI, 29.1-30.1]), oral (5.2 [5.1-5.4]), rectum (2.6 [2.5-2.7]), NHL (2.3 [2.2-2.31]), and pancreatic (1.63 [1.6-1.7]) cancers. The mean ages of cancer diagnosis and cancer-related death were significantly younger among CHeCS HCV cohort patients compared to the general population for many cancers. Incidence and mortality of many types of non-liver cancers were higher, and age at diagnosis and death younger, in patients with chronic HCV infection compared to the general population. Copyright © 2015. Published by Elsevier B.V.
Article
Full-text available
The clinical course of chronic hepatitis C virus (HCV) infection is characterized by possible development of both liver and extrahepatic disorders. The tropism of HCV for the lymphoid tissue is responsible for several immune-mediated disorders; a poly-oligoclonal B-lymphocyte expansion, commonly observed in a high proportion of patients with HCV infection, are responsible for the production of different autoantibodies and immune-complexes, such as mixed cryoglobulins. These serological alterations may characterize a variety of autoimmune or neoplastic diseases. Cryoglobulinemic vasculitis due to small-vessel deposition of circulating mixed cryoglobulins is the prototype of HCV-driven immune-mediated and lymphoproliferative disorders; interestingly, in some cases the disease may evolve to frank malignant lymphoma. In addition, HCV shows an oncogenic potential as suggested by several clinico-epidemiological and laboratory studies; in addition to hepatocellular carcinoma that represents the most frequent HCV-related malignancy, a causative role of HCV has been largely demonstrated in a significant percentage of patients with isolated B-cells non-Hodgkin's lymphomas. The same virus may be also involved in the pathogenesis of papillary thyroid cancer, a rare neoplastic condition that may complicate HCV-related thyroid involvement. Patients with HCV infection are frequently asymptomatic or may develop only hepatic alteration, while a limited but clinically relevant number can develop one or more autoimmune and/or neoplastic disorders. Given the large variability of their prevalence among patients' populations from different countries, it is possible to hypothesize a potential role of other co-factors, i.e., genetic and/or environmental, in the pathogenesis of HCV-related extra-hepatic diseases.
Article
Full-text available
Introduction Acute hepatitis C infection (HCV) is increasing in the HIV-infected population, particularly among men who have sex with men (MSM). Patients co-infected with HCV and HIV progress more rapidly to liver cirrhosis and are at higher risk of hepatocellular carcinoma. We looked at our management of acute HCV to assess treatment outcome. Materials and Methods We performed a retrospective and prospective case note review of HIV-HCV co-infected patients attending a large inner city sexual health clinic from 2006-to date. Acute HCV infections (less than six months) were identified and data was collected on demographics, transmission and treatment outcomes. Treatment regime was 48 weeks of weight-based ribavirin and pegylated interferon α2a. Results Sixty-seven acute HCV infections were identified among 142 co-infected patients, all of whom were male and 66 (98.5%) were MSM. Median age at diagnosis was 37 (range 20–59) and 58 (86.6%) were White British. Sixty patients (89.6%) were genotype 1, 3 (4.5%) were genotype 4 and 2 (3.0%) were genotype 2/3. A further 2 (3.0%) were re-infections. A peak in new HCV diagnoses was seen in 2013 with 17 (25.4%). Route of transmission was sexual in all cases with 13 (19.4%) also injecting drugs, pointing to mixed transmission routes. Nine (69.2%) of these occurred in 2013. Nine (13.4%) patients cleared HCV themselves. Of the 58 who didn't clear HCV, 12 (20.7%) were lost to follow up/transferred care, 4 (6.9%) declined treatment awaiting newer agents, and 10 (17.2%) are waiting to start. A total of 32 patients started treatment. Six (18.8%) patients are currently on treatment and three (9.4%) await a final sustained virological response (SVR) test. Six out of twenty-four (25.0%) stopped treatment due to lack of response and 1 stopped due to side effects. Fifteen (62.5%) achieved SVR and 2 (8.3%) failed to achieve SVR. Eight out of ten (80.0%) patients who had an early virological response (EVR) achieved SVR. Conclusions Our data shows good treatment outcomes for acute HCV infection in HIV patients with an SVR rate of 62.5%. We've seen a steady increase in acute HCV infection, particularly in MSM injecting party drugs. Changing risk behaviours, particularly a rise in chem sex parties and club drug use, along with more anonymous partners and disclosure issues create difficulties in managing the HCV epidemic. More education is needed to raise awareness of HCV transmission and disclosure in our MSM population.
Article
Full-text available
Introduction Acute hepatitis C virus (HCV) infection has emerged as a major cause of morbidity in the HIV-infected population. Most guidelines recommend early treatment with pegylated interferon and ribavirin due to higher cure rates. The impact of acute HCV and its treatment on the outcome of the HIV-infected population is unknown. With new treatment options for HCV, early treatment of acute HCV has to be questioned. Here, we report a long-term analysis on patients with acute HCV. Methods Retrospective analysis from an outpatient clinic from Berlin. All patients with the diagnosis of acute HCV according to The European AIDS Treatment Network (NEAT) criteria were included in the database at their date of HCV diagnosis and followed-up until the last medical contact. Demographic data was taken from the medical file. A fibrosis estimation was performed using transient elastography (Fibroscan(®). A Fibroscan value above 7 kPa was considered as significant fibrosis, above 12.4 kPa as liver cirrhosis. The following outcomes were documented: (a) liver-related: hepatic decompensation, cirrhosis, hepatocellular carcinoma. (b) non-liver-related: death, myocardial infarction, AIDS-defining event, psychiatric hospitalisation. Results A total of 207 cases of acute HCV infection in HIV-infected patients were diagnosed between May 2002 and September 2013. All patients were male and declared homosexual contacts as their risk factor for having acquired HIV. The mean age was 39 years, 162 patients (78%) were on antiretroviral treatment, and the median CD4 cell count was 593/mm3 (IQR 443–749). At HCV diagnosis, the highest median alanine aminotransferase (ALT) level was 408 IU/mL (159–871), the HCV viral load was 800,000 IU/mL (45x103–2.8x106). 22 cases (11%) cleared their infection spontaneously, 161 (77%) underwent interferon-based treatment. Of those treated, 58% had a sustained virological response. 36 cases of HCV reinfection were documented. All patients were followed-up over an interval of 806 patient-years. The median liver stiffness was 5.3 kPa (4–7) after a median interval of 34 months. 33 patients developed significant fibrosis, and 11 patients (6%) developed cirrhosis. Nine (5%) patients died during follow-up, and 11 developed non-liver-related endpoints. All but one deceased patients had interferon-based treatment. Conclusions Severe hepatic disease and death rarely occurs in a highly treated HCV population. As interferon-based treatment may induce side effects, it is from now on justified to await new HCV treatment options.
Article
Background: Among the large scope of extrahepatic manifestations related to hepatitis C virus (HCV) infection, many studies recently evaluated the frequency and characteristics of cardiovascular involvement. Objective: To assess the current published data on HCV infection and cardiovascular diseases. Methods: Published studies on cardiovascular disease, i.e. cerebrovascular accident and ischemic heart disease in subjects with HCV infection were analyzed from literature databases. Results: Subjects with HCV chronic infection have an increased prevalence of carotid atherosclerosis and increased intima-media thickness compared to healthy controls or those with hepatitis B or nonalcoholic steatohepatitis. Active chronic HCV infection appears as an independent risk factor for ischemic cerebrovascular accidents. Active chronic HCV infection is associated with increased risk of ischemic heart disease. In some studies, successful interferon-based therapy showed a beneficial impact on the cardiovascular risk. Conclusion: The risk of major cardiovascular events is higher in patients with HCV infection compared to controls, independent of the severity of the liver disease or the common cardiovascular risk factors. The beneficial impact of interferon-based therapy needs to be confirmed with new direct antiviral interferon-free agents in prospective studies with extended follow-up. This article is protected by copyright. All rights reserved.
Article
Background: The probability of spontaneous hepatitis C virus (HCV) clearance ranges from 11% to 49%. Our previous cross-sectional study suggests that mode of acquisition explains some of this heterogeneity. We performed this prospective study to determine factors associated with spontaneous HCV clearance among men who have sex with men (MSM). Methods: A mixture-cure model was used to evaluate the probability of spontaneous HCV clearance among 101 MSM in the Multicenter AIDS Cohort Study with acute HCV infection between 1984 and 2012. Results: Spontaneous HCV clearance occurred in 46% of MSM (49% in non-injection drug users [IDUs] and 23% in IDUs). In the multivariable analysis, age <30 years (clearance ratio [CR] = 2.43; 95% confidence interval [CI], 1.53-3.87) and being human immunodeficiency virus (HIV) uninfected (CR = 2.97; 95% CI, 1.98-4.46) were independently associated with spontaneous clearance. Among men aged ≥30 years, being HIV uninfected, not having unprotected anal intercourse, older age, and being on highly active antiretroviral therapy were independently associated with higher clearance. The interferon lambda rs12979860 single nucleotide polymorphism (SNP) was not associated with spontaneous clearance among the 88 MSM who were not active IDUs (CR = 0.74; 95% CI, .46-1.21 for CC vs CT/TT genotype). Conclusions: The high probability of spontaneous HCV clearance together with the lack of an association between the rs12979860 SNP and spontaneous clearance among MSM who do not use injection drugs suggests that the immune mechanisms involved with a successful response to acute HCV differ by mode of virus acquisition. Understanding potential mechanistic differences could be important for HCV vaccine development.
Article
Co-infection HIV/HCV or HBV is frequent because of the common ways of transmission of these various viruses. HIV-infected patients are living longer since the introduction of highly active antiretroviral therapy. However, co-infection with the hepatitis C virus (HCV) or hepatitis B virus leads to increased mor-bidity from liver disease and higher overall mortality. Noxious interactions between these viruses are currently well-known in particular acceleration by the HIV of the natural history of HCV or HBV infection. Recent progress was made in the diagnosis and management of the patients Co-infected by HIV/HCV or HBV. Although remarkable, this progress does not occult the need for continuing the preven-tive measures to reduce the acquisition of new infections and the development of new drugs more effective and better-tolerated to ensure a more important therapeutic success for all the Co-infected patients. La co-infection VIH/VHC ou VHB est fréquente du fait des voies communes de transmission de ces différents virus. Actuellement l'infection chronique du foie par le VHC ou le VHB est devenue la cause d'une importante morbidité et mortalité des patients porteurs du VIH du fait de l'augmentation de leur survie et la diminution de leur mortalité depuis l'introduction des TAR. Des interactions délétères entre ces virus sont actuellement bien connues notamment l'accélération par le VIH de l'histoire natu-relle de l'infection par le VHC ou VHB . Des progrès récents ont été réalisés dans la prise en charge diagnostique et thérapeutique des patients co-infectés par VIH/VHC ou VHB. Bien que remar-quables, ces progrès n'occultent pas la nécessité de poursuivre les mesures préventives visant à réduire l'acquisition de nouvel-les infections et le développement de nouvelles molécules plus efficaces et mieux tolérées pour assurer un succès thérapeutique plus important chez l'ensemble des patients co-infectés.